Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2

Klein et al., Journal of Urology, doi:10.1097/JU.0000000000001338, Feb 2021
ProphylaxisRetrospective · 1,779 patients · USA · Mar – Jun 2020
Antiandrogens for COVID-19
Outcome
Improvement
Relative Risk · 95% CI
00.511.52+
← Antiandrogens
reduce risk
Antiandrogens
increase risk →
Higher mortality with antiandrogens
Not statistically significant · p = 0.12

Antiandrogens for COVID-19

7th treatment shown to reduce risk in September 2020, now with p = 0.000000056 from 49 studies.

No treatment is 100% effective.
Protocols combine treatments.

Retrospective 1,779 prostate cancer patients, showing no significant differences in COVID-19 outcomes with ADT.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
OutcomeImprovementEffect · pTreatmentControl
risk of death 123.9% higher · RR 2.24 · p = 0.12 123.9% higherRR 2.24p = 0.12 6 of 304 (2.0%) 13 of 1,475 (0.9%) treatment 6 of 304 (2.0%), control 13 of 1,475 (0.9%)
risk of case 6.6% lower · RR 0.93 · p = 0.80 6.6% lowerRR 0.93p = 0.80 17 of 304 (5.6%) 85 of 1,475 (5.8%) treatment 17 of 304 (5.6%), control 85 of 1,475 (5.8%)NNT 586adjusted per studyodds ratio converted to relative riskmultivariable

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Klein et al., 1 Feb 2021, retrospective, USA, peer-reviewed, 7 authors, study period 12 March, 2020 - 10 June, 2020.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
DOI record: { "DOI": "10.1097/ju.0000000000001338", "ISSN": [ "0022-5347", "1527-3792" ], "URL": "http://dx.doi.org/10.1097/ju.0000000000001338", "alternative-id": [ "10.1097/JU.0000000000001338" ], "author": [ { "affiliation": [ { "name": "Department of Urology, Glickman Urological and Kidney Institute, Cleveland, Ohio" } ], "family": "Klein", "given": "Eric A.", "sequence": "first" }, { "affiliation": [ { "name": "Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, Ohio" } ], "family": "Li", "given": "Jianbo", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, Ohio" } ], "family": "Milinovich", "given": "Alex", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, Ohio" } ], "family": "Schold", "given": "Jesse D.", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Cancer Biology and Genitourinary Malignancies Research Center,Lerner Research Institute, Cleveland, Ohio" } ], "family": "Sharifi", "given": "Nima", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, Ohio" } ], "family": "Kattan", "given": "Michael W.", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Neurology, Neurological Institute Cleveland Clinic and Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio" } ], "family": "Jehi", "given": "Lara", "sequence": "additional" } ], "container-title": [ "Journal of Urology" ], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2020, 9, 8 ] ], "date-time": "2020-09-08T20:09:40Z", "timestamp": 1599595780000 }, "deposited": { "date-parts": [ [ 2022, 3, 25 ] ], "date-time": "2022-03-25T00:27:05Z", "timestamp": 1648168025000 }, "indexed": { "date-parts": [ [ 2022, 3, 25 ] ], "date-time": "2022-03-25T19:28:38Z", "timestamp": 1648236518979 }, "is-referenced-by-count": 19, "issn-type": [ { "type": "print", "value": "0022-5347" }, { "type": "electronic", "value": "1527-3792" } ], "issue": "2", "issued": { "date-parts": [ [ 2021, 2 ] ] }, "journal-issue": { "issue": "2", "published-print": { "date-parts": [ [ 2021, 2 ] ] } }, "language": "en", "member": "276", "original-title": [], "page": "441-443", "prefix": "10.1097", "published": { "date-parts": [ [ 2021, 2 ] ] }, "published-print": { "date-parts": [ [ 2021, 2 ] ] }, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "http://www.jurology.com/doi/10.1097/JU.0000000000001338" } }, "score": 1, "short-container-title": [ "Journal of Urology" ], "short-title": [], "source": "Crossref", "subject": [ "Urology" ], "subtitle": [], "title": [ "Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2" ], "type": "journal-article", "volume": "205" }